Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes. - Wikidata - awgldk - TriplyDB

Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes.

Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes.

http://www.wikidata.org/entity/Q39284051

about

Ischaemic postconditioning: cardiac protection after the event Ischaemic conditioning: pitfalls on the path to clinical translation Remote ischaemic conditioning in the context of type 2 diabetes and neuropathy: the case for repeat application as a novel therapy for lower extremity ulceration Diabetic cardiomyopathy: pathophysiology and clinical features Unique transcriptional profile of sustained ligand-activated preconditioning in pre- and post-ischemic myocardium.Type 2 diabetic obese db/db mice are refractory to myocardial ischaemic post-conditioning in vivo: potential role for Hsp20, F1-ATPase δ and Echs1 Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations.Diabetic hyperglycemia attenuates sympathetic dysfunction and oxidative stress after myocardial infarction in rats.Ischemic conditioning: the challenge of protecting the diabetic heart.Remote ischemic conditioning.Inhibition of mitochondrial permeability transition pore restores the cardioprotection by postconditioning in diabetic hearts Hyperglycemia raises the threshold of levosimendan- but not milrinone-induced postconditioning in rat hearts PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer The role of comorbidities in cardioprotection Involvement of Glycogen Synthase Kinase-3β and Oxidation Status in the Loss of Cardioprotection by Postconditioning in Chronic Diabetic Male Rats.Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning.Influence of tumour necrosis factor alpha on the outcome of ischaemic postconditioning in the presence of obesity and diabetes.Up-regulation of microRNA-135a protects against myocardial ischemia/reperfusion injury by decreasing TXNIP expression in diabetic mice.Metabolic syndrome influences cardiac gene expression pattern at the transcript level in male ZDF rats Remote ischemic preconditioning in patients with intermittent claudication.New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop Long-term insulin treatment restores cardioprotection induced by sufentanil postconditioning in diabetic rat heart.Susceptibility to myocardial ischemia reperfusion injury at early stage of type 1 diabetes in rats.A role for GRK2 in myocardial ischemic injury: indicators of a potential future therapy and diagnostic.Diabetic inhibition of preconditioning- and postconditioning-mediated myocardial protection against ischemia/reperfusion injury.The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury.Myocardial postconditioning: next step to cardioprotection.Autophagy as a therapeutic target for ischaemia /reperfusion injury? Concepts, controversies, and challenges.Molecular mechanisms of ischemic conditioning: translation into patient outcomes.Erectile dysfunction and its management in patients with diabetes mellitus.Ischemic Conditioning Attenuates Platelet-Mediated Thrombosis: A Tale of Reverse Translation.Sarcolemmal dependence of cardiac protection and stress-resistance: roles in aged or diseased hearts.Delta Opioid Receptors and Cardioprotection.Ischemic postconditioning: mechanisms, comorbidities, and clinical application.Parathyroid Hormone-Related Peptide: A Novel Endocrine Cardioprotective "Conditioning Mimetic".Platelets, diabetes and myocardial ischemia/reperfusion injury.Far red/near infrared light-induced protection against cardiac ischemia and reperfusion injury remains intact under diabetic conditions and is independent of nitric oxide synthase The effects of ischemic postconditioning on myocardial function and nitric oxide metabolites following ischemia-reperfusion in hyperthyroid rats.Role of Tissue and Systemic Hypoxia in Obesity and Type 2 Diabetes.High-dose fasudil preserves postconditioning against myocardial infarction under hyperglycemia in rats: role of mitochondrial KATP channels.

P2860

Q26853129-0E944542-8545-407E-93F6-2DC8C7CA801B Q27000466-96F42719-A6A5-4FE9-A5BC-D832311AECFB Q28078462-7C43AECB-94C4-4E0F-A378-83065A0E482A Q30457504-9C97E13D-284A-407A-948C-E6BEF8132194 Q31132643-079127C7-0029-4E29-84C5-4D3885730739 Q33948666-8560C370-B5D9-4819-BDFC-9AAE8146B175 Q34247485-DA674E5A-3664-4133-8D40-30611E382AB6 Q34346513-FEB95415-D357-4006-A40D-492D0AA93339 Q34457775-1678A405-514F-4255-8651-BB5FA6D64FFD Q34458416-59C838F1-29E5-4610-9B78-3E11BDCDDCFD Q34586543-F220FA37-C96B-4A27-A761-6FD687962981 Q35717077-D2BF436B-785B-4AFF-B355-DCC8D2714981 Q35827798-EC917C60-E68F-4A6F-AAFC-C2A787FEBAD3 Q36099360-28AF245B-4B46-4E7B-9651-5C5BD39201AA Q36196031-11991047-09F6-4CA5-8380-6EFF87430F42 Q36288965-E9E314AC-17F6-4348-8DCD-0168FA0C0722 Q36355264-2BCA2A70-4454-4B12-B3D8-4F5C3AC17956 Q36516693-DC72AFD9-41C3-4418-BFEA-0A65E5BE07E1 Q36691127-80BFF1BB-7D33-4FB5-9A55-8EBA16E2FD6F Q36791645-CF78B79C-861D-43D1-BA52-9CCE976D9902 Q37007953-E0DFA056-D304-465E-B73D-57B418651866 Q37107072-1B3B08B0-05FF-468D-A1DB-14B2F5CA4E1E Q37357405-54B1DEC0-8007-4A6A-B691-B30FD048C704 Q37907329-770B2182-16F2-4BDF-9FC7-566821E2CDEC Q37913053-B8A7B2D5-BF04-4272-B0A6-F3CCDB2BFCED Q37926558-431C10F6-FB0D-4C89-AA5E-67DD9A5A160A Q37942779-A2DCCE2A-AE38-4689-8DB4-26E55547C67C Q37973049-8C5958A0-436B-4E04-BAF3-089F804DC7CA Q38120093-3AE20D8C-ECEC-4FC9-9DE5-2507ED6B8945 Q38615555-DABB5356-C325-4337-8DAD-C10B61C00744 Q38631884-E0F61069-B896-4054-A1F1-81A3024A82DB Q38903618-5A768059-6F10-44D0-BA13-0EB19F1AFDF7 Q39151222-EA7B4590-03F6-4418-98DA-9A0E27A0F54A Q39232678-C62F45C0-14A5-4715-A1E8-A5BB9958A714 Q39238269-2DAF4468-2309-4EDD-ACDB-4702DA47BBBD Q39343342-375FEFFF-A5D9-41F8-A9A1-DCE827F1809D Q41902563-D296FC85-3727-4366-87A6-6A0178E82CDC Q41905279-97A63B88-747C-4D83-824B-10502A0F7A5C Q42058398-40E02A9E-F9D0-47EC-9FD3-7E76C7258CA5 Q42158475-912A7C2F-82A7-455E-A9FA-A2DE562562A2

P2860

Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes.

http://www.wikidata.org/entity/Q39284051

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Cardioprotection with postcond ...... of type-2 and type-1 diabetes.

@en

Cardioprotection with postcond ...... of type-2 and type-1 diabetes.

@nl

type

label

Cardioprotection with postcond ...... of type-2 and type-1 diabetes.

@en

Cardioprotection with postcond ...... of type-2 and type-1 diabetes.

@nl

prefLabel

Cardioprotection with postcond ...... of type-2 and type-1 diabetes.

@en

Cardioprotection with postcond ...... of type-2 and type-1 diabetes.

@nl

P1433

Q39284051-54B6C35A-B473-40F1-AF98-1903E06A2BA3

P1476

Q39284051-54B181E2-FF3C-4ECC-9532-022D99D35CA6

P2093

Q39284051-2F4B863D-0850-4A0C-8E6A-3CE2FAA8F43C

Q39284051-A17DAD8B-1251-4D29-A505-AECED38879D7

Q39284051-AA5D96CD-BEF7-43C5-8619-7BB886AA77C5

Q39284051-E11A08DB-252E-4553-BCE6-C9E351E86460

P2860

Q39284051-059905AE-9952-49BE-9611-BE5FEEFC480D

Q39284051-08741381-D444-4C1B-A814-C90E0C39C3F2

Q39284051-0D9132CF-816B-4EDB-A652-26ED6A1136D2

Q39284051-13F7F0AB-2B6B-47A6-9277-FE5EECAD536F

Q39284051-1C527F57-3D97-4C67-B251-56D9D11BF41E

Q39284051-1F4B610C-BAB1-4CBB-92A0-0957794061B4

Q39284051-25CE6689-8514-492D-9F3E-F90B555E415E

Q39284051-28E960DE-151D-48D8-9B2A-0C4D44260401

Q39284051-2F449694-45CC-4272-B762-9F0741436317

Q39284051-2F6D23BA-7AE4-4010-815B-A24869102ACA

P304

Q39284051-A49998DD-A14E-4388-9615-BC02BB538CF0

P31

Q39284051-29173927-84E9-4815-8895-FC32FC1B8A13

P356

Q39284051-AD30FFB9-43A0-4C68-A6EC-B92E7015A836

P433

Q39284051-F8953E33-048C-465A-AD52-B44F0B7C1352

P478

Q39284051-D31F80D7-D9B3-4252-BE87-4AD43F3605C8

P577

Q39284051-D3CC30F9-2025-4680-9113-3E3A9D3F901B

P5875

Q39284051-F3A6A395-5AE6-4342-B8A9-E13DE56B84E4

P698

Q39284051-6B106A2A-0668-47C4-A5BB-655988A2F984

P921

Q39284051-48039CC2-760E-4BA6-9C7F-31505E38A82C

Q39284051-E71C81BA-E86F-4DDE-BFBD-879EE9A66CF3

P932

Q39284051-AFFF7E29-315D-437A-9F99-DEEBD0888989

P356

P1433

Antioxidants & Redox Signaling

P1476

Cardioprotection with postcond ...... of type-2 and type-1 diabetes.

@en

P2093

Dale L Greiner

http://www.w3.org/2001/XMLSchema#string

Karin Przyklenk

http://www.w3.org/2001/XMLSchema#string

Michelle Maynard

http://www.w3.org/2001/XMLSchema#string

Peter Whittaker

http://www.w3.org/2001/XMLSchema#string

P2860

Heart Disease and Stroke Statistics--2010 Update: A Report From the American Heart Association

Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning

Hyperglycemia inhibits anesthetic-induced postconditioning in the rabbit heart via modulation of phosphatidylinositol-3-kinase/Akt and endothelial nitric oxide synthase signaling.

Dual specificity phosphatases: a gene family for control of MAP kinase function.

Regulation of stress-activated protein kinase signaling pathways by protein phosphatases.

Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: Does it go beyond the RISK pathway?

Postconditioning--A new link in nature's armor against myocardial ischemia-reperfusion injury.

Diverse physiological functions for dual-specificity MAP kinase phosphatases.

Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning.

What are the biochemical mechanisms responsible for enhanced fatty acid utilization by perfused hearts from type 2 diabetic db/db mice?

P304

781-790

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/ARS.2010.3343

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44800958

http://www.w3.org/2001/XMLSchema#string

P698

20578962

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

type-2 diabetes

P932

3052273

http://www.w3.org/2001/XMLSchema#string